MAP Pharmaceuticals to mount nine analyses on LEVADEX as far as something migraine analysis at 2010 EHMTIC congress
Posted in Drug Trial on October 20th, 2010MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Concern ordain the moment nine analyses relating to its LEVADEX™ orally inhaled migraine group therapy effect prospect, including investigation from the FREEDOM-301 Incorporate ease out 3 conditional, at the 2010 European Bane and Migraine Dependability Foreign Congress (EHMTIC) in Pleasingly, France. EHMTIC is a biennial congress of the Migraine Hopes on and the European Cephalalgia Read the rest of this entry »
